Cathy Eng, MD
Enriched profileProfessor of Medicine, Division of Hematology and Oncology; David H. Johnson Professor of Surgical and Medical Oncology; Associate Director for Strategic Relations and Research Partnerships, Vanderbilt-Ingram Cancer Center · Vanderbilt-Ingram Cancer Center
Cathy Eng is Professor of Medicine, Division of Hematology and Oncology; David H. Johnson Professor of Surgical and Medical Oncology; Associate Director for Strategic Relations and Research Partnerships, Vanderbilt-Ingram Cancer Center at Vanderbilt-Ingram Cancer Center. OpenAlex indexes 827 publications with 26,943 citations (h-index 77); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Cathy Eng, MD, is Professor of Medicine, Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center / Vanderbilt University Medical Center. The public record shows 827 publications with 26,943 citations (h-index 77), centered on Colorectal Cancer Treatments and Studies, Colorectal and Anal Carcinomas, Cancer Genomics and Diagnostics. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 31 companies, 2 NIH-funded awards (2024–2025).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Colorectal Cancer Treatments and Studies
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 31 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 261.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Speaker
congressional briefing "Addressing Representation in Clinical Trials," organized by the Alliance for Cancer Care Equity, April 15
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗ - Participant
White House Cancer Moonshot Colorectal Cancer Forum (April 2023), advocating for improved clinical trial participation and funding
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gioncologynow.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Sponsor: A2 Biotherapeutics Inc.
- EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
31 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year20254 payments$32,065openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim International GmbHProgram year20252 payments$11,588openpaymentsdata.cms.gov ↗
- ARRAY BIOPHARMA INCProgram year20253 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Nucleoside Analog Antiviral100%Lonsurf100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
2 NIH research awards on record, funded 2024–2025 per NIH RePORTER. The latest:
- Cultivating programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials
Vanderbilt University Medical Center
FY2025$130,426R50CA285499 - Cultivating programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials
Vanderbilt University Medical Center
FY2024$130,426R50CA285499 - Gastrointestinal Cancer Research Program
Vanderbilt University Medical Center
FY2024$89,432P30CA068485
Congress activity
Updated 27 Aug 2026
240 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Access to fertility preservation services among commercially insured adults with early-onset colorectal cancer.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.
Journal of clinical oncology
Clinical Trial2026 - Bridging the Gap: Transforming Total Neoadjuvant Therapy: NEOTERIC Signals a Step Forward in the Treatment of Locally Advanced Rectal Cancer.
Journal of clinical oncology
Article2026 - NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
Journal of clinical oncology
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/cathy-eng-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/videos/2023-asco-annual-meeting/cathy-eng-and-thejus-jayakrishnan-on-colorectal-cancer-metabolomic-differences-in-young-onset-vs-average-onset-disease
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Other
vicc.org/member/cathy-eng
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - LinkedIn
LinkedIn profile (cathy-eng-18b23b89), posts about Tamron Hall Show colorectal cancer segment
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vanderbilthealth.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
- Fellow
American College of Physicians (FACP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
Editorial & leadership roles
journal and society appointments- Co-Director
GI Oncology, Vanderbilt-Ingram Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Co-Leader
Gastrointestinal Cancer Research Program, VICC
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗ - Director
Young Adult Cancers Program, VICC
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vicc.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tamronhallshow.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncbrothers.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH